Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.

Détails

ID Serval
serval:BIB_D1FB33C27208
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.
Périodique
Clinical cancer research
Auteur(s)
Martinez P., Peters S., Stammers T., Soria J.C.
ISSN
1078-0432 (Print)
ISSN-L
1078-0432
Statut éditorial
Publié
Date de publication
01/05/2019
Peer-reviewed
Oui
Volume
25
Numéro
9
Pages
2691-2698
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Immunotherapy has fundamentally changed the treatment landscape for many patients with cancer. mAbs targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 immune checkpoints have received regulatory approval across a wide range of tumor types, including non-small cell lung cancer (NSCLC). Indeed, treatment approaches for a majority of patients with newly diagnosed metastatic NSCLC are evolving rapidly. Only for the small proportion of patients with metastatic NSCLC and genomic-driven tumors with EGFR or anaplastic lymphoma kinase (ALK)-sensitizing mutations (5%-15%), and possibly BRAF mutations and ROS rearrangements, have initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the preferred therapy. For the remaining patients, an immunotherapy-based regimen alone or in combination with chemotherapy is now the preferred option based on high-level evidence obtained from randomized controlled trials and in accordance with all available guidelines. Deciding between therapeutic options can be difficult due to the lack of direct cross-comparison studies, differences in chemotherapies and stratification factors, and differences in study populations resulting from inclusion criteria such as histology, PD-L1 expression, or tumor mutational burden (TMB). In an attempt to aid the decision-making process, we discuss and summarize the most recent data from studies using immunotherapies for the treatment of patients with previously untreated metastatic NSCLC.
Mots-clé
Antineoplastic Agents, Immunological/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, Biomarkers, Tumor/antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/secondary, Humans, Immunotherapy/methods, Lung Neoplasms/drug therapy, Lung Neoplasms/immunology, Lung Neoplasms/pathology, Prognosis
Pubmed
Web of science
Open Access
Oui
Création de la notice
08/02/2019 17:26
Dernière modification de la notice
07/07/2020 5:20
Données d'usage